You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Oriola Q2’24: Sales growth in both segments
Av Rauli Juva
Oriola’s Q2 earnings were quite in line with our estimates and the guidance for the whole year of 2024 remained unchanged. The joint venture company in Sweden performed better than we expected after two very weak quarters. CEO Katarina Gabrielson comments on the Q2 result in this interview.
Content:
00:00 Intro
00:09 Prohibited sale of Svensk dos AB
01:33 Q2 highlights
02:18 Growth in sales and invoicing
03:00 Joint venture company in Sweden
04:23 Outlook for dose dispensing business in Sweden